絞り込み

16379

広告

「"Goetz MP "[Author]」の検索結果

101件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.

A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.

SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.

NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer.

CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1.

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.

Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial.

Ductal carcinoma in situ of the breast and gene expression markers for prediction of invasive recurrence.

Genetic polymorphisms in the long noncoding RNA MIR2052HG offer a pharmacogenomic basis for the response of breast cancer patients to aromatase inhibitor therapy.

Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.

Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.

Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.

Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Gene Expression Profiling Identifies Responsive Patients with Cancer of Unknown Primary Treated with Carboplatin, Paclitaxel, and Everolimus: NCCTG N0871 (Alliance).

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
Sort by
※並べ替えは表示に時間がかかります